Telomir Pharmaceuticals, Inc.
TELO
$1.22
$0.032.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -73.74% | -69.01% | -68.20% | -92.80% | 471.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -65.19% | -52.40% | -26.53% | -80.91% | 243.84% |
| Operating Income | 65.19% | 52.40% | 26.53% | 80.91% | -243.84% |
| Income Before Tax | 66.04% | 54.54% | 28.88% | 81.60% | -249.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 66.04% | 54.54% | 28.88% | 81.60% | -249.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.04% | 54.54% | 28.88% | 81.60% | -249.89% |
| EBIT | 65.19% | 52.40% | 26.53% | 80.91% | -243.84% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -365.54% | 60.66% | 37.05% | 83.19% | -245.40% |
| Normalized Basic EPS | 83.24% | 60.70% | 36.99% | 83.16% | -245.10% |
| EPS Diluted | -365.54% | 60.66% | 37.05% | 83.19% | -245.40% |
| Normalized Diluted EPS | 83.24% | 60.70% | 36.99% | 83.16% | -245.10% |
| Average Basic Shares Outstanding | 102.72% | 15.52% | 12.92% | 9.42% | 1.35% |
| Average Diluted Shares Outstanding | 102.72% | 15.52% | 12.92% | 9.42% | 1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |